Lei Peng, Ayton Scott, Moon Steve, Zhang Qihao, Volitakis Irene, Finkelstein David I, Bush Ashley I
Oxidation Biology Unit, Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Melbourne, Victoria, Australia.
Mol Neurodegener. 2014 Aug 14;9:29. doi: 10.1186/1750-1326-9-29.
We recently reported that Parkinsonian and dementia phenotypes emerge between 7-12 months of age in tau-/- mice on a Bl6/129sv mixed background. These observations were partially replicated by another group using pure Bl6 background tau-/- mice, but notably they did not observe a cognitive phenotype. A third group using Bl6 background tau-/- mice found cognitive impairment at 20-months of age.
To reconcile the observations, here we considered the genetic, dietary and environmental variables in both studies, and performed an extended set of behavioral studies on 12-month old tau+/+, tau+/-, and tau-/- mice comparing Bl6/129sv to Bl6 backgrounds. We found that tau-/- in both backgrounds exhibited reduced tyrosine hydroxylase-positive nigral neuron and impaired motor function in all assays used, which was ameliorated by oral treatment with L-DOPA, and not confounded by changes in body weight. Tau-/- in the C57BL6/SV129 background exhibited deficits in the Y-maze cognition task, but the mice on the Bl6 background did not.
These results validate our previous report on the neurodegenerative phenotypes of aged tau-/- mice, and show that genetic background may impact the extent of cognitive impairment in these mice. Therefore excessive lowering of tau should be avoided in therapeutic strategies for AD.
我们最近报道,在Bl6/129sv混合背景的tau基因敲除小鼠中,帕金森病和痴呆表型在7至12个月大时出现。另一组使用纯Bl6背景的tau基因敲除小鼠部分重复了这些观察结果,但值得注意的是,他们没有观察到认知表型。第三组使用Bl6背景的tau基因敲除小鼠在20个月大时发现了认知障碍。
为了协调这些观察结果,我们在此考虑了两项研究中的遗传、饮食和环境变量,并对12个月大的tau+/+、tau+/-和tau-/-小鼠进行了一系列扩展的行为学研究,比较了Bl6/129sv和Bl6背景。我们发现,两种背景下的tau基因敲除小鼠在所有使用的检测中,酪氨酸羟化酶阳性黑质神经元数量均减少,运动功能受损,口服左旋多巴可改善这种情况,且不受体重变化的影响。C57BL6/SV129背景下的tau基因敲除小鼠在Y迷宫认知任务中表现出缺陷,但Bl6背景下的小鼠没有。
这些结果证实了我们之前关于老年tau基因敲除小鼠神经退行性表型的报道,并表明遗传背景可能影响这些小鼠认知障碍的程度。因此,在阿尔茨海默病的治疗策略中应避免过度降低tau水平。